KR937000141A - 비면역 유발성 운반체에 결합된 면역 유발원의 t세포 에피토프-결핍 유사물을 포함하며 면역유발원에 대한 체액성 아네르기를 유발하는 조성물 - Google Patents

비면역 유발성 운반체에 결합된 면역 유발원의 t세포 에피토프-결핍 유사물을 포함하며 면역유발원에 대한 체액성 아네르기를 유발하는 조성물

Info

Publication number
KR937000141A
KR937000141A KR1019920702481A KR920702481A KR937000141A KR 937000141 A KR937000141 A KR 937000141A KR 1019920702481 A KR1019920702481 A KR 1019920702481A KR 920702481 A KR920702481 A KR 920702481A KR 937000141 A KR937000141 A KR 937000141A
Authority
KR
South Korea
Prior art keywords
composition
immunogenic
source
immunogenic source
cell
Prior art date
Application number
KR1019920702481A
Other languages
English (en)
Other versions
KR100234678B1 (ko
Inventor
아리른 바스타드 폴
마이클 아이버선 길버트
Original Assignee
라 졸라 파마슈티컬 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/652,648 external-priority patent/US5268454A/en
Application filed by 라 졸라 파마슈티컬 캄파니 filed Critical 라 졸라 파마슈티컬 캄파니
Publication of KR937000141A publication Critical patent/KR937000141A/ko
Application granted granted Critical
Publication of KR100234678B1 publication Critical patent/KR100234678B1/ko

Links

Abstract

내용 없음.

Description

비면역 유발성 운반체에 결합된 면역 유발원의 T세포 에피토프-결핍 유사물을 포함하며 면역유발원에 대한 체액성 아네르기를 유발하는 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 실시예1에 설명되어있는 면역된 CAF1 마우스에 있는 B세포 에피토프의 검색을 예증하는 그래프,
제2도는 유사하게 실시예1에 설명되어있는 T세포 에피토프의 검색을 예증하는 그래프,
제3도는 실시예1에 설명된 “L-53”펩티드에 대한 항체의 저해를 예증하는 그래프,
제4 및 5도는 실시예4에 기술된 결과를 나타내는 그래프.

Claims (12)

  1. 면역유발원에 대해 특이한 B세포 아네르기를 유발시키기 위한 조성물에 있어서, 비면역유발성의 생물학적으로 안정한 폴리머 및(a)면역유발원이 특이하게 결합하는 B세포에 특이하게 결합하고 (b)세포 에피토프가 없는 면역유발원 유사물의 결합체로 이루어지는 것을 특징으로 하는 조성물.
  2. 제1항에 있어서, 면역유발원은 외부의 면역유발원인 것을 특징으로 하는 조성물.
  3. 제2항에 있어서, 외부의 면역유발원은 생물학적 약제, 알레르겐 또는 특별중의 대조 매질인 것을 특징으로 하는 조성물.
  4. 제1항에 있어서, 면역유발원은 자기-면역유발원인 것을 특징으로 하는 조성물.
  5. 제4항에 있어서, 자기 면역유발원은 감상선염, 당뇨병, 발작, 남성 불임증, 중증성 근무력증, 류머티스열, 또는 Rh 용혈성 질환과 연관된 것임을 특징으로 하는 조성물.
  6. 제1항에 있어서, 면역유발원 및 유사물을 동일한 화학적 부류에 속하는 것을 특징으로 하는 조성물.
  7. 제6항에 있어서, 면역유발원 및 유사물은 폴리펩티드인 것을 특징으로 하는 조성물.
  8. 제1항에 있어서, 면역유발원 및 유사물은 다른 화하걱 부류에 속하는 것을 특징으로 하는 조성물.
  9. 제1항에 있어서, 폴리머는 D-리신 및 D-글루타민산의 코폴리머인 것을 특징으로 하는 조성물.
  10. 기체에서 면역유발원에 대해 특이한 B세포 아네르기를 유발시키는 방법에 있어서, 제1,2,3,4,5,6,7,8 또는 9항의 조성물을 치료에 효과적인 양으로 개체에 투여하는 것으로 이루어지는 것을 특징으로 하는 방법.
  11. 면역유발원에 반응하여 불원의 항체가 생성되는 항체-매개의 질환을 갖는 개체을 치료하는 방법에 있어서, 제1,2,3,4,5,6,7,8또는 9항의 조성물을 치료에 효과적인 양으로 개체에 투여하는 것으로 이루어지는 것을 특징으로 하는 방법.
  12. 항체-매개의 질환을 치료하기 위한 약학적 조성물에 있어서, 약학적으로 허용되는 운반체와 결합한 제1,2,3,7,5,6,7,8 또는 9항의 결합체가 치료에 효과적이 양으로 포함하는 것을 특징으로 하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920702481A 1991-02-08 1992-02-04 비면역원성 담체에 결합된 면역원의 t세포 에피토프-결핍 유사체를 포함하는 면역원에 대한 체액성 아네르기를 유발하는 조성물 KR100234678B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US652,648 1991-02-08
US07/652,648 US5268454A (en) 1991-02-08 1991-02-08 Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
US652648 1991-02-08
PCT/US1992/000975 WO1992013558A1 (en) 1991-02-08 1992-02-04 A composition for inducing humoral anergy

Publications (2)

Publication Number Publication Date
KR937000141A true KR937000141A (ko) 1993-03-13
KR100234678B1 KR100234678B1 (ko) 1999-12-15

Family

ID=24617613

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920702481A KR100234678B1 (ko) 1991-02-08 1992-02-04 비면역원성 담체에 결합된 면역원의 t세포 에피토프-결핍 유사체를 포함하는 면역원에 대한 체액성 아네르기를 유발하는 조성물

Country Status (13)

Country Link
US (5) US5268454A (ko)
EP (1) EP0498658B1 (ko)
JP (1) JP2544873B2 (ko)
KR (1) KR100234678B1 (ko)
AT (1) ATE142109T1 (ko)
AU (1) AU646157B2 (ko)
CA (1) CA2076648C (ko)
DE (1) DE69213272T2 (ko)
DK (1) DK0498658T3 (ko)
ES (1) ES2094287T3 (ko)
GR (1) GR3021809T3 (ko)
IE (1) IE920419A1 (ko)
WO (1) WO1992013558A1 (ko)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022544A (en) * 1983-01-24 2000-02-08 The John Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US5268454A (en) 1991-02-08 1993-12-07 La Jolla Pharmaceutical Company Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
WO1993012145A1 (en) * 1991-12-19 1993-06-24 Baylor College Of Medicine Pva or peg conjugates of peptides for epitope-specific immunosuppression
DE4302012C1 (de) * 1993-01-26 1994-07-21 Serosearch Gmbh Entwicklung Un Immunologischer Test
KR100361933B1 (ko) 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
US5874409A (en) * 1995-06-07 1999-02-23 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
US6410775B1 (en) * 1995-06-07 2002-06-25 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
US5817752A (en) * 1996-06-06 1998-10-06 La Jolla Pharmaceutical Company Cyclic polypeptides comprising a thioether linkage and methods for their preparation
CA2256449A1 (en) * 1996-06-06 1997-12-11 Lajolla Pharmaceutical Company Apl immunoreactive peptides, conjugates thereof and methods of treatment for apl antibody-mediated pathologies
EP1087791B1 (en) * 1998-04-15 2005-09-21 Mayo Foundation for Medical Education and Research Inhibition of xenoreactive antibodies
US6936249B1 (en) * 1998-04-15 2005-08-30 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
EP1073459A4 (en) * 1998-04-27 2005-01-19 Biocrystal Ltd COMPOSITIONS AND METHODS OF TOLERATING IN IMMUNOMOPLEX-MEDIATED ILLNESS
US6858210B1 (en) 1998-06-09 2005-02-22 La Jolla Pharmaceutical Co. Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
DE69928995T2 (de) * 1998-06-22 2006-09-07 Affymetrix, Inc., Santa Clara Reagenz und Verfahren zu fester Phase Synthese
US6458953B1 (en) 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
US6399578B1 (en) * 1998-12-09 2002-06-04 La Jolla Pharmaceutical Company Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
US20010010818A1 (en) * 1998-12-09 2001-08-02 Engle Steven B. Methods and formulations for reducing circulating antibodies
US7083777B1 (en) * 1999-04-02 2006-08-01 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
CA2376057A1 (en) * 1999-06-08 2000-12-14 La Jolla Pharmaceutical Company Valency platform molecules comprising aminooxy groups
WO2001041813A2 (en) * 1999-11-28 2001-06-14 La Jolla Pharmaceutical Company Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof
WO2001093914A2 (en) 2000-06-08 2001-12-13 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
CA2425208C (en) * 2000-09-26 2013-04-09 Duke University Rna aptamers and methods for identifying the same
SV2003000753A (es) 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
CN1511041A (zh) * 2001-05-17 2004-07-07 ������ҩ�����޹�˾ 利用抑制cd21的药剂治疗抗体介导的病变的方法
CA2448567C (en) * 2001-05-25 2014-05-20 Duke University Modulators of nucleic acid ligands
US20030114405A1 (en) * 2001-08-13 2003-06-19 Linnik Matthew D. Methods of treating systemic lupus erythematosus in individuals having significantly impaired renal function
US7105135B2 (en) * 2001-10-16 2006-09-12 Lockheed Martin Corporation System and method for large scale detection of hazardous materials in the mail or in other objects
WO2004060320A2 (en) * 2002-12-27 2004-07-22 La Jolla Pharmaceutical Company Methods of improving health-related quality of life in individuals with systemic lupus erythematosus
US20060160087A1 (en) * 2003-01-31 2006-07-20 Mcgrath Michael Monitoring and treatment of amyotrophic lateral sclerosis
WO2004089422A2 (en) * 2003-03-30 2004-10-21 La Jolla Pharmaceutical Co. Methods of treating and monitoring systemic lupus erythematosus in individuals
JP2006522135A (ja) * 2003-03-31 2006-09-28 ザ ブライアム アンド ウィミンズ ホスピタル インコーポレーテッド 喘息およびアレルギーの処置のための両性イオン免疫調節剤
ATE377023T1 (de) * 2003-11-05 2007-11-15 Pevion Biotech Ltd Zusammensetzungen, die von melittin abgeleitet sind und peptide enthalten, und verfahren zur potenzierung von immunreaktionen gegen target- antigene
SI1745062T1 (sl) * 2004-04-22 2014-09-30 Regado Biosciences, Inc. Izobljšani modulatorji koagulacijskih faktrojev
ITPD20040159A1 (it) * 2004-06-21 2004-09-21 Univ Degli Studi Trieste Derivati bifunzionali del polietilenglicole loro preparazione e uso.
WO2007092451A2 (en) 2006-02-06 2007-08-16 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
EP2057998A1 (en) * 2007-10-31 2009-05-13 Universitätsklinikum Hamburg-Eppendorf Use of modified cells for the treatment of multiple sclerosis
EP2731617A4 (en) 2011-07-12 2015-07-01 Brigham & Womens Hospital LIPID-CONTAINING PSA COMPOSITIONS, METHODS OF ISOLATION AND METHODS OF USING SAME
US10857177B2 (en) 2015-08-19 2020-12-08 President And Fellows Of Harvard College Lipidated PSA compositions and methods
US11491181B2 (en) 2016-07-15 2022-11-08 President And Fellows Of Harvard College Glycolipid compositions and methods of use
US10864279B2 (en) * 2016-12-16 2020-12-15 Industrial Technology Research Institute Linker-drug and antibody-drug conjugate (ADC) employing the same
EP3715374A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the sequestration of undesirable antibodies in a patient
US11986536B2 (en) 2019-03-23 2024-05-21 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
EP3715376A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the prevention or treatment of myasthenia gravis
EP3715375A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the prevention or treatment of pre-eclampsia
IL301332A (en) 2020-09-23 2023-05-01 Ablevia Biotech Gmbh A compound for preventing or treating conditions mediated by autoantibodies
TW202228784A (zh) 2020-09-23 2022-08-01 奧地利商艾柏力維亞生技有限公司 用以於一患者中螯合非預期的抗ｐｅｇ抗體的化合物
JP2023542388A (ja) 2020-09-23 2023-10-06 アブレヴィア バイオテック ゲーエムベーハー 第ｖｉｉｉ因子補充療法の有効性を増加させるための化合物
CA3192748A1 (en) 2020-09-23 2022-03-31 Oskar SMRZKA Compound for increasing efficacy of viral vectors
WO2022063879A1 (en) 2020-09-23 2022-03-31 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
US20230381328A1 (en) 2020-09-24 2023-11-30 Ablevia Biotech Gmbh Compound for the prevention or treatment of myasthenia gravis
WO2023180502A1 (en) 2022-03-24 2023-09-28 Ablevia Biotech Gmbh Compound for increasing efficacy of oncolytic viruses

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4351A (en) * 1846-01-07 Straw-cutter
US107389A (en) * 1870-09-13 Improved hat and cap-bracket
US103990A (en) * 1870-06-07 Improvement in liquid-meters
US162953A (en) * 1875-05-04 Improvement in fire-alarm telegraphs
US31635A (en) * 1861-03-05 Straw-cutter
US2002A (en) * 1841-03-12 Tor and planter for plowing
US26856A (en) * 1860-01-17 Btjoying ships
US2003A (en) * 1841-03-12 Improvement in horizontal windivhlls
US82400A (en) * 1868-09-22 Improvement in kossfflg-maoeines
US2005A (en) * 1841-03-16 Improvement in the manner of constructing molds for casting butt-hinges
US4388441A (en) * 1977-02-03 1983-06-14 Scripps Clinic & Research Foundation Induction of immunological tolerance
US4191668A (en) * 1977-02-03 1980-03-04 Scripps Clinic And Research Foundation Induction of immunological tolerance
US4220565A (en) * 1979-01-18 1980-09-02 Scripps Clinic & Research Foundation Immunochemical conjugates: method and composition
US4430260A (en) * 1979-02-27 1984-02-07 Lee Weng Y Penicillin-polyvinyl alcohol conjugate and process of preparation
JPS56145222A (en) * 1980-04-28 1981-11-11 Toshiyuki Hamaoka Improved antibody and its preparation
GB2102825A (en) 1981-07-31 1983-02-09 Ici Plc Polymer-modified polyols
US6022544A (en) * 1983-01-24 2000-02-08 The John Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US5126131A (en) * 1983-01-24 1992-06-30 The Johns Hopkins University Therapeutic suppression of specific immune responses by administration of antigen-competitive conjugates.
US4650675A (en) * 1983-08-18 1987-03-17 The Children's Medical Center Corporation Oligonucleotide conjugates
US4599231A (en) * 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
FR2562421B1 (fr) * 1984-04-09 1989-02-17 Sandoz Sa Perfectionnements a la therapie par l'interleukine
GB8411550D0 (en) * 1984-05-04 1984-06-13 Stylo Matchmakers Int Injection moulding apparatus
US4803070A (en) * 1986-04-15 1989-02-07 Ribi Immunochem Research Inc. Immunological emulsion adjuvants for polysaccharide vaccines
US5017648A (en) * 1986-05-30 1991-05-21 La Jolla Pharmaceutical Company D-GL conjugate therapy
US4950713A (en) * 1986-05-30 1990-08-21 La Jolla Pharmaceutical Company Conjugates of D-glutamic acid: D-lysine copolymer and certain biochemicals
US4950469A (en) * 1986-05-30 1990-08-21 La Jolla Pharmaceutical Company D-GL conjugate therapy
US4886782A (en) * 1987-02-26 1989-12-12 The United States Of America As Represented By The Department Of Health And Human Services Malarial immunogen
JPS6468398A (en) * 1987-09-08 1989-03-14 Agency Ind Science Techn Monoclonal anti-idiotype antibody and hybridoma and use thereof
USD321129S (en) 1988-06-28 1991-10-29 Henkel Kommanditgesellschaft Auf Aktien Container for dispensing liquid detergent or similar article
US5102663A (en) * 1988-10-18 1992-04-07 Sloan-Kettering Instutute For Cancer Research Vaccine for stimulating or enhancing production of antibodies against 9-O-acetyl GD3
DE473721T1 (de) * 1989-05-25 1993-04-29 Sloan-Kettering Institute for Cancer Research, New York, N.Y. Antiidiotypischer antikoerper, der eine immunantwort gegen ein glykosphingolipid induziert und seine verwendung.
JP2704779B2 (ja) * 1989-12-15 1998-01-26 本田技研工業株式会社 加速度検知装置
US5268454A (en) 1991-02-08 1993-12-07 La Jolla Pharmaceutical Company Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
US5162515A (en) 1990-01-16 1992-11-10 La Jolla Pharmaceutical Company Conjugates of biologically stable polymers and polynucleotides for treating systemic lupus erythematosus
US5552391A (en) 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
JPH05508621A (ja) * 1990-03-02 1993-12-02 オートイミューン　インク 自己抗原の経口投与による自己免疫疾患のダウンコントロール
US5177188A (en) * 1990-12-03 1993-01-05 The Scripps Research Institute Methods and compositions for diagnosing chronic immune thrombocytopenic purpura
JPH06503833A (ja) * 1990-12-17 1994-04-28 ザ ジョンズ ホプキンス ユニバーシティ 制御された化学のオリゴマー形態の抗原での免疫応答抑制
DK0563254T3 (da) * 1990-12-19 1996-02-12 Schering Corp Anvendelse af IL-4 til forstærkning af immunrespons på immunogener i vacciner
AU664184B2 (en) 1991-07-15 1995-11-09 La Jolla Pharmaceutical Company Modified phosphorous intermediates for providing functional groups on the 5' end of oligonucleotides
US5736146A (en) * 1992-07-30 1998-04-07 Yeda Research And Development Co. Ltd. Conjugates of poorly immunogenic antigens and synthetic peptide carriers and vaccines comprising them
US5778723A (en) 1992-07-31 1998-07-14 Aluminum Company Of America Method and apparatus for necking a metal container and resultant container
US5718352A (en) 1994-11-22 1998-02-17 Aluminum Company Of America Threaded aluminum cans and methods of manufacture
KR100361933B1 (ko) 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
US5874409A (en) 1995-06-07 1999-02-23 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
US6410775B1 (en) 1995-06-07 2002-06-25 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
US6858210B1 (en) 1998-06-09 2005-02-22 La Jolla Pharmaceutical Co. Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
US6138847A (en) 1999-02-25 2000-10-31 Johnson; Russell Joe Disposable non-reusable baby bottle
USD424444S (en) 1999-05-27 2000-05-09 Mott's Inc. Combined bottle and cap
WO2006003368A2 (en) 2004-07-01 2006-01-12 The University Court Of The University Of Edinburgh Improved c-element and logic reduction and completion detection circuits

Similar Documents

Publication Publication Date Title
KR937000141A (ko) 비면역 유발성 운반체에 결합된 면역 유발원의 t세포 에피토프-결핍 유사물을 포함하며 면역유발원에 대한 체액성 아네르기를 유발하는 조성물
JP2544873B2 (ja) 液性アネルギ―を誘導するための組成物
FI120137B (fi) Mutanttienterotoksiini, joka on tehokas ei-toksisena suun kautta annettavana adjuvanttina
Grey et al. Antigen processing and presentation to T cells
EP2848627A3 (en) Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
KR960704568A (ko) 이종 t-세포 에피토우프를 사용하여 자가 단백질에 대해 항체 반응을 유도하는 방법(inducing antibody response against self-proteins with the aid of foreign t-cell epitores)
DK169784A (da) Peptider til farmaceutisk behandling af pattedyr
US6048529A (en) PVA or PEG conjugates of peptides for epitope-specific immunosuppression
KR920004418A (ko) 브래디키닌 길항제
BR9810907A (pt) Anticorpos monoclonais e policlonais, peptìdeo suscetìvel de gerar um anticorpo, agente imunogênico, sequência de nucleotìdeos, composição farmacêutica, uso de pelo menos um anticorpo, kit de diagnóstico, e, processo para preparar um agente imunogênico
JP2004026797A (ja) ペプチドｐ２７７類似体及びこれを含む糖尿病の治療又は診断のための薬剤組成物
ES2118939T3 (es) Peptido para el diagnostico e inmunizacion contra la infeccion con t.cruzi.
Benjamini et al. Antigenic determinants of proteins of defined sequences
ATE94880T1 (de) Synthetische peptide, gegen diese gerichtete antikoerper und deren verwendung.
Thole et al. Heat shock proteins in immunopathology
Bacha et al. Anti‐arthritic effects demonstrated by an interleukin‐2 receptor‐targeted cytotoxin (DAB486IL‐2) in rat adjuvant arthritis
St Georgiev Immunomodulatory activity of small peptides
KR910003092A (ko) 항체 정제 방법에 사용하기 위한 hcg펩티드
KR930703444A (ko) 어류 황체화 호르몬-방출 호르몬 동족체
Braley-Mullen et al. A thyroxine-containing thyroglobulin peptide induces both lymphocytic and granulomatous forms of experimental autoimmune thyroiditis
FR2694938B1 (fr) Nouveaux peptides, anticorps diriges contre ces peptides, anticorps anti-idiotypiques, application a titre de medicaments, compositions pharmaceutiques et kits de diagnostic les renfermant.
ATE192164T1 (de) Synthetische peptide und diese enthaltende pharmazeutische zusammensetzungen
Perper et al. ANALYSIS OF THE BIOLOGICAL ACTIVITY OF ANTILYMPHOCYTE SERUM: II Influence of Cell Type and Method of Immunization
Coleman Protein haptenation by drugs.
KR900011477A (ko) 항-트립타아제 항체 및 이것을 사용한 후천성 면역결핍증 치료용 조성물